Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Drugs Made In America Acquisition Corp. (DMAA)

DMAA amends Power Analytics merger deal, adds sponsor share forfeiture and rights offer

Neutral Impact 4 of 5 m&a Written later

Drugs Made In America Acquisition Corp. filed Amendment No. 3 to its merger agreement with Power Analytics Global Corp, dated July 14, 2026. The amendment requires the former sponsor to forfeit at least 50% of its founder shares, sets a $0.25 to $0.35 per-right tender offer for public rights, and restates minimum cash at a $30 million target and $15 million floor. Shareholders are affected by these changes to dilution, cash at closing, and the affiliated-party structure, which the filing says includes a fairness opinion condition.

Key points

  • Sponsor must forfeit at least 50% of founder shares and surrender 430,000 private placement rights for no consideration.
  • The company agreed to launch a cash tender, exchange offer, or consent solicitation for public rights at $0.25 to $0.35 per right, before or with the proxy mailing.
  • Minimum cash target is $30,000,000 with a $15,000,000 floor.
  • A contingent Amendment No. 4 for a possible three-party combination takes effect only if conditions are met by September 30, 2026.

The filing

CompanyDrugs Made In America Acquisition Corp. (DMAA)
Form8-K, current report
Filed with the SECJul 20, 2026, 5:00 PM ET
Accession number0001213900-26-079678

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.